AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15235926
Drug: Baked skim
RxNorm normalized name: skim milk
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baked skim soy with soy sauce (protein, 86.9 g)
Trial: 15235926
Drug: Beefsteak (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beefsteak (200 g)
Trial: 10980457
Drug: Regular fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular fluticasone (250 microg twice daily for two weeks)
Trial: 10980457
Drug: Single fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single fluticasone (250 microg 30 min before allergen inhalation)
Trial: 2413692
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin applied under occlusion
Trial: 31030961
Drug: α‐bungarotoxin (α7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐bungarotoxin (α7 nicotinic acetylcholine receptor antagonist)
Trial: 25795717
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusions for counts <10×10(9)/L
Trial: 25795717
Drug: Days with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days with platelet count <10×10(9)/L
Trial: 23851346
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/kg, 1‐h IV infusion) with cyclosporine (5 mg/kg, 2‐h infusion)
Trial: 23851346
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/kg, 1‐h IV infusion) without cyclosporine (control)
Trial: 19207890
Drug: Mechanical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical periodontal treatment with local application of minocycline (APT)
Trial: 8256504
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of Recombivax HB given at 3 or 4 years
Trial: 11164146
Drug: Terazosin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin treatment
Trial: 18663165
Drug: Colesevelam hydrochloride,
RxNorm normalized name: Colesevelam Hydrochloride, 625 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride, 3.75 g/d
Trial: 18852398
Drug: Colesevelam hydrochloride,
RxNorm normalized name: Colesevelam Hydrochloride, 625 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride, 3.75 g/d (metformin monotherapy cohort)
Trial: 18852398
Drug: Colesevelam hydrochloride,
RxNorm normalized name: Colesevelam Hydrochloride, 625 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride, 3.75 g/d (combination therapy cohort)
Trial: 12064336
Drug: Eggshell powder-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eggshell powder-enriched supplement (group A; n=24)
Trial: 12064336
Drug: Purified CaCO3-enriched
RxNorm normalized name: Purified oxgall
DrugBank: Ox bile extract (DB14016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified CaCO3-enriched supplement (group B; n=22)
Trial: 10598691
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of 2% dorzolamide (three times daily) and 0.5% timolol (twice daily)
Trial: 8707080
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 1 g twice daily
Trial: 8707080
Drug: Sulphasalazine 1
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphasalazine 1 g twice daily
Trial: 1684492
Drug: Bunazosin hydrochloride
RxNorm normalized name: bunazosin hydrochloride
DrugBank: Bunazosin (DB12230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin hydrochloride 0.025%, 0.05%, 0.1%, and 0.2% (topical administration)
Trial: 1684492
Drug: Bunazosin hydrochloride
RxNorm normalized name: bunazosin hydrochloride
DrugBank: Bunazosin (DB12230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin hydrochloride 0.1% (multiple doses)
Trial: 25197740
Drug: Mechanical cleaning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical cleaning with interdental brushes combined with cetylpyridinium chloride (0.3% CPC) gel
Trial: 19299272
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) with anti-inflammatory agent (60 mg oral acemetacine twice daily for 10 days)
Trial: 19299272
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (Ca-nadroparin 190 IUAxa/kg in a single dose)
Trial: 17516022
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg once-yearly for 2, 3 or 5 years
Trial: 17516022
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg once-yearly
Trial: 15468607
Drug: Trazodone (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (50-100 mg)
Trial: 15468607
Drug: Zaleplon (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon (10-20 mg)
Trial: 28167747
Drug: Hospital-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-based treatment as usual
Trial: 29911601
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone (OXY)
Trial: 29911601
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (IVM) followed by codeine
Trial: 21140258
Drug: Sublingual Salvinorin
RxNorm normalized name: Salvinorin A
DrugBank: Salvinorin A (DB12327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Salvinorin A (SA) up to 4 mg
Trial: 18245546
Drug: OGX-011 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OGX-011 at 640 mg
Trial: 18245546
Drug: Docetaxel (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (30 mg/m2 weekly for 5 of 6 weeks or 75 mg/m2 every 3 weeks)
Trial: 16989201
Drug: Dry air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry air radon baths (DARB) with radon concentration 40 nCi/l
Trial: 16989201
Drug: Dry air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry air radon baths (DARB) with radon concentration 20 nCi/l
Trial: 12975739
Drug: Rapacuronium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 1.5 mg/kg with neostigmine
Trial: 12975739
Drug: Rapacuronium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 1.5 mg/kg without neostigmine
Trial: 6594473
Drug: 2 million
RxNorm normalized name: Carticel 12 million cells/vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 million units aqueous penicillin G intravenously every four hours for a total of 12 doses (two days) postoperatively
Trial: 6594473
Drug: Placebo intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenously every four hours for a total of 12 doses (two days) postoperatively
Trial: 27879604
Drug: Negative-pressure wound
RxNorm normalized name: Microcyn Negative-Pressure Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-pressure wound therapy for 5 days after primary closure
Trial: 19032906
Drug: Krypton yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton yellow laser photocoagulation around the hole margin with oral placebo (vitamin B1)
Trial: 19032906
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (vitamin B1) only
Trial: 12523894
Drug: Chronic suppressive
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic suppressive oral acyclovir
Trial: 12523894
Drug: Chronic suppressive
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic suppressive oral acyclovir targeting patients with a history of stromal keratitis
Trial: 6340249
Drug: O‐(beta‐Hydroxyethyl)‐rutoside administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O‐(beta‐Hydroxyethyl)‐rutoside administered intravenously daily before each radiation
Trial: 17592099
Drug: Pravastatin, vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin, vitamin E, and homocysteine lowering therapy
Trial: 20067456
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (150 mg twice daily)
Trial: 9647605
Drug: Cysteinyl leukotriene
RxNorm normalized name: bis(cysteinyl maleimide) PEG 20000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteinyl leukotriene receptor antagonist (zafirlukast)
Trial: 7663802
Drug: 5-lipoxygenase inhibitor
RxNorm normalized name: 5-lipoxygenase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-lipoxygenase inhibitor (zileuton)
Trial: 9647605
Drug: Antileukotriene agents
RxNorm normalized name: ANTIASTHMA,ANTILEUKOTRIENES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antileukotriene agents (general)
Trial: 2542682
Drug: naloxone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone (0.8 mg i.v.)
Trial: 1146722
Drug: Tocopherol-stripped safflower
RxNorm normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocopherol-stripped safflower oil containing 88 g of polyunsaturated fatty acids and 2.3 mg of tocopherols.
Trial: 30418340
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of modified Sinaki exercises and Nordic Walking
Trial: 23342765
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drugs only)
Trial: 26404895
Drug: Daily exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exercise programme
Trial: 22310310
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide synthase (NOS) inhibition via intra-arterial infusion of N(G)-monomethyl-L-arginine (L-NMMA)
Trial: 20027346
Drug: IFN inductor
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN inductor anaferon (pediatric formulation)
Trial: 770083
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg indomethacin per day
Trial: 9017526
Drug: Sustained-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release methylphenidate (MSR) 20-40 mg/day
Trial: 9017526
Drug: Sustained-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release methylphenidate (MSR)
Trial: 8506913
Drug: Pentoxifylline 2000
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 2000 mg
Trial: 2969740
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg doxazosin
Trial: 2951051
Drug: Doxazosin (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (2, 4, and 8 mg)
Trial: 23994382
Drug: Pegasys (PegIFNα)
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegasys (PegIFNα) weekly dosing of 360 μg
Trial: 23994382
Drug: Viread (tenofovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viread (tenofovir disoproxil fumarate, TDF) daily dose of 300 mg
Trial: 23994382
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Pegasys and Viread
Trial: 22743137
Drug: Early hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early hCG administration (hCG 5000 IU, IM when leading follicle diameter 16.0-16.9 mm)
Trial: 22743137
Drug: Late hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late hCG administration (hCG 5000 IU, IM when leading follicle diameter 18.0-18.9 mm)
Trial: 16630151
Drug: PLA(2) peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLA(2) peptide vaccine
Trial: 10618542
Drug: HIV SF2
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV SF2 gp120/MF59 vaccine (50 microg)
Trial: 8839901
Drug: Fadrozole 1
RxNorm normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole 1 mg twice daily
Trial: 3323603
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and metoprolol (beta adrenergic antagonists)
Trial: 29866385
Drug: Brief behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief behavioral treatment (BT) based on motivational interviewing and cognitive behavioral therapy
Trial: 29866385
Drug: Medication-assisted treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-assisted treatment (MAT) with extended-release injectable naltrexone (XR-NTX) for alcohol use disorder or buprenorphine/naloxone (BUP/NX) for opioid use disorder
Trial: 26673981
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of IVIG (n = 32)
Trial: 25671931
Drug: Deferiprone (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone (75 mg/kg in three divided doses orally)
Trial: 25671931
Drug: Deferrioxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferrioxamine (50 mg/kg/24hrs for 5 days/week as parental infusion)
Trial: 19384263
Drug: MeNZB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MeNZB vaccine (25 mug) administered with routine immunizations and a fourth dose at 10 months (n = 250)
Trial: 17569575
Drug: Computer reminders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer reminders for antibiotic prescriptions
Trial: 17569575
Drug: Computer reminders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer reminders for asthma/COPD prescriptions
Trial: 17569575
Drug: Specific recommendations
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific recommendations (quinolones for cystitis, corticosteroids for COPD, antibiotics for acute sore throat)
Trial: 9764988
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (10 mg kg(‐1).d(‐1), given in single daily doses)
Trial: 9764988
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (10 mg kg(‐1).d(‐1), given in multiple daily doses)
Trial: 3265347
Drug: Low-dose perioperative
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose perioperative interferon-alpha (r-HuIFN alpha), 2 megaunits daily for 1 week starting the evening before surgery
Trial: 29473352
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (Baclofen 10 mg, 3 times a day for 4 weeks)
Trial: 27261998
Drug: Ayurvedic herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic herbal compound preparation (Murraya koenigii, Punica granatum, Curcuma longa), administered as a decoction twice daily for 4 weeks
Trial: 27261998
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered as ground powders for 4 weeks
Trial: 27261998
Drug: Ayurvedic herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic herbal compound preparation
Trial: 17928573
Drug: Risperidone augmentation
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone augmentation (0.25-1 mg)
Trial: 8838964
Drug: Peroral amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroral amoxicillin 0.75 g 3 times daily (n = 50)
Trial: 1627419
Drug: Modified radical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified radical mastectomy or partial mastectomy plus radiation therapy
Trial: 6476838
Drug: Mitoxantrone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone at dosages of 2 to 4 mg/m2 with a 5‐day schedule or 6 to 12 mg/m2 with a one day schedule, repeating at 4‐week intervals
Trial: 31206579
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (information about local substance use treatment services)
Trial: 26945358
Drug: Lactated Ringer
RxNorm normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer solution (LR)
Trial: 19155234
Drug: DAS-driven therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAS-driven therapy (group A)
Trial: 17698144
Drug: Topical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobial scrub with 4% chlorhexidine
Trial: 16361166
Drug: Bupivacaine (0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.75% 6 mg, diluted to 2 ml with distilled water)
Trial: 12099982
Drug: Tacrolimus (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (dosage not specified)
Trial: 10641952
Drug: 0.625mg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625mg of conjugated equine estrogens plus 2.5mg of medroxyprogesterone daily (Prempro)
Trial: 7772614
Drug: Selective MAO-A
RxNorm normalized name: Mao cang zhu rhizome
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective MAO-A inhibitors (moclobemide, brofaromine)
Trial: 2304788
Drug: Mother and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mother and child treated in separate but concurrent session
Trial: 30981585
Drug: Second generation
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second generation antipsychotics (SGAs) - haloperidol, flupentixol
Trial: 30981585
Drug: First generation
RxNorm normalized name: First generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First generation antipsychotics (FGAs) - aripiprazole, olanzapine, quetiapine
Trial: 18794865
Drug: Etoposide and
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide and G-CSF
Trial: 18794865
Drug: Etoposide, G-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide, G-CSF and rituximab
Trial: 16931805
Drug: Graphic instructions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graphic instructions for missed pill guidance
Trial: 16931805
Drug: Text-only instructions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text-only instructions for missed pill guidance
Trial: 9460867
Drug: Russian vaccine
RxNorm normalized name: Russian thistle pollen extract
DrugBank: Salsola kali pollen (DB10388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Russian vaccine 'Combiotech'
Trial: 9460867
Drug: American vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: American vaccine 'H-B-Vax II'
Trial: 9460867
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (schedule 0-1-2 months)
Trial: 9460867
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (schedule 0-1-6 months)
Trial: 9460867
Drug: Children receiving
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children receiving only the vaccines
Trial: 8404168
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline (TE)
Trial: 30776537
Drug: Previous weak
RxNorm normalized name: weakleaf bur ragweed pollen extract
DrugBank: Ambrosia confertiflora pollen (DB10872)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous weak opioid therapy
Trial: 25243960
Drug: Fuzhenghuayu capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzhenghuayu capsule plus propranolol
Trial: 25243960
Drug: Fuzhenghuayu capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzhenghuayu capsule alone
Trial: 7640497
Drug: Compound salviae
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound salviae miltiorrhizae injection